Literature DB >> 23065360

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

Owen A Moore1, Nicole Goh, Tamera Corte, Hannah Rouse, Oliver Hennessy, Vivek Thakkar, Jillian Byron, Joanne Sahhar, Janet Roddy, Eli Gabbay, Peter Youssef, Peter Nash, Jane Zochling, Susanna M Proudman, Wendy Stevens, Mandana Nikpour.   

Abstract

OBJECTIVES: In a multi-centre study, we sought to determine whether extent of disease on high-resolution CT (HRCT) lung, reported using a simple grading system, is predictive of decline and mortality in SSc-related interstitial lung disease (SSc-ILD), independently of pulmonary function tests (PFTs) and other prognostic variables.
METHODS: SSc patients with a baseline HRCT performed at the time of ILD diagnosis were identified. All HRCTs and PFTs performed during follow-up were retrieved. Demographic and disease-related data were prospectively collected. HRCTs were graded according to the percentage of lung disease: >20%: extensive; <20%: limited; unclear: indeterminate. Indeterminate HRCTs were converted to limited or extensive using a forced vital capacity threshold of 70%. The composite outcome variable was deterioration (need for home oxygen or lung transplantation), or death.
RESULTS: Among 172 patients followed for mean (s.d.) of 3.5 (2.9) years, there were 30 outcome events. In Weibull multivariable hazards regression modelling, baseline HRCT grade was independently predictive of outcome, with an adjusted hazard ratio (aHR) = 3.0, 95% CI 1.2, 7.5 and P = 0.02. In time-varying covariate models (based on 1309 serial PFTs and 353 serial HRCTs in 172 patients), serial diffusing capacity of the lung for carbon monoxide by alveolar volume ratio (ml/min/mmHg/l) (aHR = 0.4; 95% CI 0.3, 0.7; P = 0.001) and forced vital capacity (dl) (aHR = 0.9; 95% CI 0.8, 0.97; P = 0.008), were also strongly predictive of outcome.
CONCLUSION: Extensive disease (>20%) on HRCT at baseline, reported using a semi-quantitative grading system, is associated with a three-fold increased risk of deterioration or death in SSc-ILD, compared with limited disease. Serial PFTs are informative in follow-up of patients.

Entities:  

Mesh:

Year:  2012        PMID: 23065360     DOI: 10.1093/rheumatology/kes289

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  43 in total

1.  Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

Authors:  Beth Wallace; Suzanne Kafaja; Daniel E Furst; Veronica J Berrocal; Peter A Merkel; James R Seibold; Maureen D Mayes; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2015-02-09       Impact factor: 7.580

2.  Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Masataka Kuwana; Ning Li; Michael D Roth; Julio Charles; Faye N Hant; Galina S Bogatkevich; Tanjina Akter; Grace Kim; Jonathan Goldin; Dinesh Khanna; Philip J Clements; Daniel E Furst; Robert M Elashoff; Richard M Silver; Shervin Assassi
Journal:  Arthritis Rheumatol       Date:  2019-11-01       Impact factor: 10.995

3.  The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis.

Authors:  Thi Dan Linh Nguyen-Kim; Britta Maurer; Yossra A Suliman; Fabian Morsbach; Oliver Distler; Thomas Frauenfelder
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Connective tissue disease associated interstitial pneumonia: a challenge for both rheumatologists and pulmonologists.

Authors:  Sarah Geerts; Wim Wuyts; Ellen De Langhe; Jan Lenaerts; Jonas Yserbyt
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 5.  Personalized medicine in systemic sclerosis: facts and promises.

Authors:  Rucsandra Dobrota; Carina Mihai; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

Review 6.  Interstitial lung disease in systemic sclerosis: current and future treatment.

Authors:  Roberto Giacomelli; Vasiliki Liakouli; Onorina Berardicurti; Piero Ruscitti; Paola Di Benedetto; Francesco Carubbi; Giuliana Guggino; Salvatore Di Bartolomeo; Francesco Ciccia; Giovanni Triolo; Paola Cipriani
Journal:  Rheumatol Int       Date:  2017-01-06       Impact factor: 2.631

Review 7.  [Pulmonary fibrosis in rheumatic diseases].

Authors:  D Grund; E Siegert
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.743

8.  Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.

Authors:  Sabrina Hoa; Sasha Bernatsky; Russell J Steele; Murray Baron; Marie Hudson
Journal:  Rheumatology (Oxford)       Date:  2020-05-01       Impact factor: 7.580

Review 9.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

10.  Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Authors:  Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2017-06-16       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.